MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Pharmacotherapy"

  • 2023 International Congress

    A Retrospective Review of Amantadine in Progressive Supranuclear Palsy

    N. Mcfarland, R. Farrukh, S. Mahn (Gainesville, USA)

    Objective: To determine the efficacy and tolerability of amantadine in Progressive supranuclear palsy (PSP). Background: PSP is one of the most common atypical parkinsonian disorders,…
  • 2023 International Congress

    Effect and Mechanism of Shaoyao Gancao Decoction(SGD) in Treatment of Pain in Parkinson’s Disease Based on Network Pharmacology and Molecular Docking

    Q. Zhao (Shanghai, China)

    Objective: Based on the method of network pharmacology, this paper discusses the potential effects and mechanisms of SGD in the treatment of pain in PD. Background:…
  • 2023 International Congress

    Characterisation of the pharmacokinetic profile of L-DOPA in the common marmoset

    D. Bédard, F. Gaudette, F. Beaudry, P. Huot (Montreal, Canada)

    Objective: To determine the pharmacokinetic (PK) profile of L-3,4-dihydroxyphenylalanine (L-DOPA) in the common marmoset (Callithrix jacchus). Background: The common marmoset has been used to model…
  • 2023 International Congress

    Improvement of nocturia symptoms and associated quality of life in patients with Parkinson’s disease treated with foslevodopa/foscarbidopa: results from 2 phase 3 trials

    K. Chaudhuri, M. Bouchard, E. Freire-Alvarez, R. Pahwa, L. Bergmann, R. Gupta, P. Kukreja, M. Shah, S. Isaacson (London, United Kingdom)

    Objective: To assess nocturia over time and its correlation with quality of life (QoL) in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDP/CDP). Background:…
  • 2023 International Congress

    Continuous subcutaneous foslevodopa/foscarbidopa: final results from a phase 3, open-label study

    J. Aldred, A. Amelin, A. Antonini, B. Bergmans, F. Bergquist, M. Bouchard, K. Budur, C. Carroll, K. Chaudhuri, S. Criswell, E. Danielsen, E. Freire Alvarez, F. Gandor, J. Jia, T. Kimber, H. Mochizuki, W. Robieson, A. Spiegel, D. Standaert, S. Talapala, M. Facheris, V. Fung (Spokane, USA)

    Objective: Evaluate safety and efficacy of foslevodopa/foscarbidopa (LDP/CDP) for patients with Parkinson’s disease (PD) in a 52-week, phase 3 study. Background: As PD progresses, patients…
  • 2022 International Congress

    Collective expert perspectives on the use of safinamide as adjunctive therapy for Parkinson’s disease in Japan: Online-based Delphi approach

    A. Takeda, Y. Tsuboi, M. Nomoto, H. Mochizuki, N. Hattori (Miyagi, Japan)

    Objective: To summarize opinions on the optimal patient profile and methods of using safinamide in common clinical scenarios, Japanese movement disorder specialists with expertise in…
  • 2022 International Congress

    Therapy resistant tremor in Parkinson’s disease. Satisfying an unmet need.

    SW. Pedersen, L. Johannsen (Frederiksberg, Denmark)

    Objective: Investigation on Parkinson's patients with therapy-resistant tremor usingapomorphine-pen injection for alleviation of resting tremor. Background: In Parkinson’s disease one of the major disturbing symptoms…
  • 2022 International Congress

    Neuroprotective effect of Boswellia dalzielii extracts in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease

    GL. Ndji Otto, H. Adjia, JP. Mingoas Kilekoung (Bertoua, Cameroon)

    Objective: To evaluate the possible protective effects of Boswellia dalzielii in animal model of Parkinson Disease (PD) induced by 6-hydroxydopamine (6-OHDA) injection in the striatum…
  • 2022 International Congress

    Diagnosed and Drug-Treated Prevalence of Essential Tremor in Adult Patients: Retrospective Analyses of Two US Healthcare Claims Databases

    R. Saad, M. Markowitz, L. Gibbs, D. Fuller, W. Ni, R. Pahwa, K. Lyons, M. Baladi, J. Lin (Palo Alto, USA)

    Objective: Estimate the prevalence of diagnosed and drug-treated essential tremor (ET) in the adult population using 2 US healthcare claims databases. Background: ET is a…
  • 2022 International Congress

    Factors related to the antidepressant effect of safinamide in Parkinson’s disease. A post-hoc analysis of SADNESS-PD study

    E. Peña, C. Borrué, M. Mata, JC. Martínez-Castrillo, A. Alonso-Canovas, JL. Chico, L. López-Manzanares, M. Llanero, J. Herreros-Rodríguez, A. Esquivel, T. Maycas-Cepeda, C. Ruíz-Huete (Madrid, Spain)

    Objective: To assess the role of different factors in the antidepressant effect of safinamide in Parkinson’s disease (PD) Background: SADNESS-PD was a real-life, multicenter, retrospective…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 32
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An atypical and interesting feature of Parkinson´s disease
  • #25136 (not found)
  • Unusual prolonged survival in multiple system atrophy: A case report
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley